¼¼°èÀÇ ÇコÄɾî ÄÄÆÐ´Ï¾ð ·Îº¿ ½ÃÀå
Healthcare Companion Robots
»óǰÄÚµå : 1781235
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 374 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,180,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,541,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÇコÄɾî ÄÄÆÐ´Ï¾ð ·Îº¿ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 49¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 20¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÇコÄɾî ÄÄÆÐ´Ï¾ð ·Îº¿ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 16.0%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 49¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ µ¿¹°ÇüÀº CAGR 14.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 31¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÈÞ¸Ó³ëÀ̵åÇü ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 19.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 5¾ï 5,240¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 20.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÇコÄɾî ÄÄÆÐ´Ï¾ð ·Îº¿ ½ÃÀåÀº 2024³â¿¡ 5¾ï 5,240¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 11¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 20.9%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 12.0%¿Í 14.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 12.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ÇコÄɾî ÄÄÆÐ´Ï¾ð ·Îº¿ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

ÇコÄÉ¾î ºÐ¾ß¿¡¼­ ÄÄÆÐ´Ï¾ð ·Îº¿ÀÌ Àα⸦ ²ø°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

ÇコÄɾî ÄÄÆÐ´Ï¾ð ·Îº¿ÀÇ µîÀåÀº Á¤½ÅÀû Áö¿ø, ÀÏ»ó Ȱµ¿ Áö¿ø, Àå¾Ö ¹× ¸¸¼ºÁúȯÀ» ¾Î°í ÀÖ´Â °³ÀÎÀÇ »îÀÇ ÁúÀ» Çâ»ó½ÃÅ´À¸·Î½á ȯÀÚ Ä¡·áÀÇ º¯È­¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î °í·ÉÈ­°¡ ÁøÇàµÇ¸é¼­ °£º´ÀÎÀÇ ºÎ´ãÀ» ÁÙÀ̸鼭 ³ëÀÎÀÇ ÀÚ¸³À» µ½´Â º¸Á¶±â¼ú¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÇコÄɾî ÄÄÆÐ´Ï¾ð ·Îº¿¿¡´Â ÀΰøÁö´É(AI), À½¼º ÀνÄ, ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀÌ Å¾ÀçµÇ¾î ÀÖ¾î ȯÀÚ¿ÍÀÇ ´ëÈ­, º¹¾à ¼øÀÀÀ» À§ÇÑ ¾Ë¸² Á¦°ø, À̵¿ Áö¿ø µîÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ·Îº¿Àº ƯÈ÷ ³ëÀÎ µ¹º½¿¡ À¯¿ëÇϸç, ÀÌ¿ëÀÚ¿Í ¾ç¹æÇâ ´ëÈ­¿Í Ȱµ¿À» ÅëÇØ ¿Ü·Î¿òÀ̳ª ÀÎÁö ±â´É ÀúÇÏ¿Í ½Î¿ì´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÚÆóÁõ°ú °°Àº ½Å°æ ¹ß´Þ Àå¾Ö¸¦ °¡Áø »ç¶÷µéÀº »çȸÀû ±³·ù¿Í Ä¡·á¸¦ ÃËÁøÇÏ´Â ·Îº¿ µ¿¹ÝÀڷκÎÅÍ ÇýÅÃÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. COVID-19 »çÅ´ »ç¶÷°úÀÇ Á¢ÃËÀ» ÃÖ¼ÒÈ­ÇÏ°í µ¹º½ÀÇ ¿¬¼Ó¼ºÀ» º¸ÀåÇÏ´Â µ¥ ÀÖ¾î ·Îº¿À» ÅëÇÑ Áö¿øÀÇ Á߿伺À» ´õ¿í ºÎ°¢½ÃÄ×½À´Ï´Ù. º´¿ø, ¿ä¾ç½Ã¼³, Àç°¡ ¿ä¾ç ÇöÀå¿¡¼­´Â ȯÀÚ¿ÍÀÇ °ü°è °­È­, ½ºÆ®·¹½º °¨¼Ò, Á¤½ÅÀû Çູ°¨À» Çâ»ó½Ã۱â À§ÇØ ÄÄÆÐ´Ï¾ð ·Îº¿À» ¾÷¹«¿¡ Á¢¸ñÇÏ´Â »ç·Ê°¡ ´Ã°í ÀÖ½À´Ï´Ù. ·Îº¿ ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² ÇコÄÉ¾î ºÐ¾ß¿¡¼­ ÄÄÆÐ´Ï¾ð ·Îº¿ÀÇ ¿ªÇÒÀÌ È®´ëµÇ¾î »ç¿ëÀÚ¿¡°Ô º¸´Ù °³ÀÎÈ­µÇ°í ÀûÀÀ·ÂÀÌ ³ôÀº Áö¿øÀ» Á¦°øÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

AI, ¼¾¼­, Àΰ£°ú ·Îº¿ÀÇ »óÈ£ÀÛ¿ëÀÌ ¾î¶»°Ô ÀÌ ½ÃÀåÀ» Çü¼ºÇϰí Àִ°¡?

ÀΰøÁö´É, ¼¾¼­ ±â¼ú, Àΰ£-·Îº¿ »óÈ£ÀÛ¿ë(HRI)ÀÇ ¹ßÀüÀº ÇコÄɾî ÄÄÆÐ´Ï¾ð ·Îº¿ÀÇ ÁøÈ­¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. AI°¡ žÀçµÈ ·Îº¿Àº ÀÚ¿¬¾î¸¦ ó¸®Çϰí, °¨Á¤À» ÀνÄÇϰí, »ç¿ëÀÚÀÇ ÃëÇâÀ» ÇнÀÇϰí, »óÈ£ÀÛ¿ëÀ» º¸´Ù Àΰ£¿¡ °¡±õ°í °³ÀÎÈ­ÇÒ ¼ö ÀÖµµ·Ï ½Ã°£À» µé¿© ÇнÀÇÒ ¼ö ÀÖ½À´Ï´Ù. LiDAR, Àû¿Ü¼±, ÅÍÄ¡¼¾¼­ µîÀÇ ¼¾¼­°¡ ³»ÀåµÈ ·Îº¿Àº ÀÚÀ²ÀûÀ¸·Î °ø°£À» À̵¿ÇÏ°í ½ÅüÀû Á¦½ºÃ³¿¡ ¹ÝÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû °­È­·Î ÀÎÇØ, ¹Ý·Á·Îº¿Àº ¹°°ÇÀ» °¡Á®¿À°í, ÁÖÀǸ¦ ȯ±â½Ã۰í, Ȱ·Â¡Èĸ¦ ¸ð´ÏÅ͸µÇÏ´Â µî ÀÏ»óÀûÀÎ ¾÷¹«¸¦ Áö¿øÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀϺΠ÷´Ü ·Îº¿Àº ¸»ÇÏ±â ÆÐÅϰú ÇൿÀÇ ´Ü¼­¸¦ ºÐ¼®ÇÏ¿© Á¤½Å°Ç°­ ¹®Á¦ÀÇ Ãʱâ ¡Èĸ¦ °¨ÁöÇÒ ¼ö ÀÖ´Â ·Îº¿µµ ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý AI¸¦ ÅëÇÕÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ·Îº¿ÀÇ ´É·ÂÀº ´õ¿í °­È­µÇ¾î ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ ½Ç½Ã°£ ¾÷µ¥ÀÌÆ® ¹× ¿ø°Ý ¸ð´ÏÅ͸µÀ» ÇÒ ¼ö ÀÖ°Ô µË´Ï´Ù. ´º·Î·Îº¸Æ½½º ¿¬±¸µµ ÀÎÁö±â´É ÀúÇϸ¦ °¨ÁöÇϰí Ä¡·áÀû °³ÀÔÀ» ÇÏ´Â ·Îº¿ÀÇ ±æÀ» ¿­¾î°¡°í ÀÖ½À´Ï´Ù. HRIÀÇ Áö¼ÓÀûÀÎ °³¹ß·Î ÄÄÆÐ´Ï¾ð ·Îº¿ÀÇ »çȸÀû ¼ö¿ë¼ºÀÌ Çâ»óµÇ°í, º¸´Ù Á÷°üÀûÀÌ°í °¨Á¤ÀûÀ¸·Î ¹ÝÀÀÇÏ°Ô µÉ °ÍÀÔ´Ï´Ù. AI¿Í ·Îº¿ °øÇÐÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó, ÇコÄɾî ÄÄÆÐ´Ï¾ð ·Îº¿ÀÌ °£º´ ÆÀÀÇ ÇʼöÀûÀÎ ±¸¼º¿øÀÌ µÉ °¡´É¼ºÀº Á¡Á¡ ´õ Ä¿Áö°í ÀÖ½À´Ï´Ù.

ÇコÄÉ¾î ·Îº¿ µµÀÔÀÇ À±¸®Àû, ±ÔÁ¦Àû °úÁ¦´Â ¹«¾ùÀΰ¡?

ÇコÄÉ¾î ºÐ¾ß¿¡¼­ÀÇ ÄÄÆÐ´Ï¾ð ·Îº¿ÀÇ À¯¸ÁÇÑ ÀÀ¿ë¿¡µµ ºÒ±¸Çϰí, ¸î °¡Áö À±¸®Àû, ±ÔÁ¦Àû °úÁ¦¸¦ ÇØ°áÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ·Îº¿Àº ȯÀÚÀÇ ±â¹Ð µ¥ÀÌÅ͸¦ ¼öÁýÇϰí ó¸®Çϱ⠶§¹®¿¡ ÇÁ¶óÀ̹ö½Ã ¹®Á¦°¡ ¹ß»ýÇÒ ¼ö ÀÖÀ¸¸ç, ¾ö°ÝÇÑ »çÀ̹ö º¸¾È Á¶Ä¡¿Í ÀǷẸÇè »óÈ£¿î¿ë¼º ¹× Ã¥ÀÓ¿¡ °üÇÑ ¹ý·ü(HIPAA), ÀÏ¹Ý µ¥ÀÌÅÍ º¸È£ ±ÔÁ¤(GDPR) µîÀÇ ±ÔÁ¦¸¦ ÁؼöÇØ¾ß ÇÕ´Ï´Ù. ¶ÇÇÑ, ·Îº¿¿¡ ´ëÇÑ Á¤¼­Àû ÀÇÁ¸°ú Àΰ£°ü°è¿¡ ¹ÌÄ¥ ¼ö ÀÖ´Â ÀáÀçÀû ¿µÇâ¿¡ ´ëÇÑ À±¸®Àû ³íÀǵµ °è¼ÓµÇ°í ÀÖ½À´Ï´Ù. ÀϺΠÀü¹®°¡µéÀº ¹Ý·Á·Îº¿ÀÌ °£º´ÀÎÀ» ´ëüÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó °£º´ÀÎÀÇ ³ë·ÂÀ» º¸¿ÏÇÏ´Â ¿ªÇÒÀ» ÇØ¾ß ÇÑ´Ù°í ÁÖÀåÇϰí ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ·Îº¿ÀÇ ±ÔÁ¦ »óȲÀº ¾ÆÁ÷ °³¹ß ÁßÀ̸ç, ±¹°¡º°·Î ¾ÈÀü±âÁذú ÀÎÁõ±âÁØÀÌ »óÀÌÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ·Îº¿ÀÌ ÀÇ·á±â±â ºÐ·ù ±âÁذú À±¸®Àû °¡À̵å¶óÀÎÀ» ÃæÁ·Çϵµ·Ï º¸ÀåÇÏ´Â °ÍÀº Á¦Á¶¾÷ü¿¡°Ô ¿©ÀüÈ÷ Å« µµÀü °úÁ¦ÀÔ´Ï´Ù. ¶ÇÇÑ, ·Îº¿ ½Ã½ºÅÛÀÇ °¡°ÝÀÌ ºñ½Î±â ¶§¹®¿¡ ƯÈ÷ Àú¼Òµæ Áö¿ª¿¡¼­´Â ÀÌ¿ëÇÏ±â ¾î·Æ´Ù´Â ¹®Á¦Á¡ÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ Á¤ºÎ¿Í ±ÔÁ¦ ±â°üÀº ÇコÄÉ¾î ·Îº¿ÀÇ ¾ÈÀüÇϰí À±¸®ÀûÀÎ µµÀÔÀ» À§ÇÑ ¸íÈ®ÇÑ °¡À̵å¶óÀÎÀ» ¼ö¸³ÇÏ´Â µ¿½Ã¿¡, ÀÌ ½ÅÈï ±â¼ú¿¡ ´ëÇÑ ÇÕ¸®ÀûÀÎ °¡°Ý°ú °øÆòÇÑ Á¢±Ù¼ºÀ» º¸ÀåÇØ¾ß ÇÕ´Ï´Ù.

ÇコÄɾî ÄÄÆÐ´Ï¾ð ·Îº¿ ½ÃÀåÀÇ ±Þ¼ºÀå ¿øµ¿·ÂÀº?

ÇコÄɾî ÄÄÆÐ´Ï¾ð ·Îº¿ ½ÃÀåÀÇ ¼ºÀåÀº °í·ÉÈ­ Àα¸ Áõ°¡, AI ¹× ·Îº¿ °øÇÐÀÇ ¹ßÀü, ÇコÄɾî Áö¿ø ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´ µî ½Å°æ ÅðÇ༺ ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÎÁöÀû Àڱذú ½ÅüÀû Áö¿øÀ» Á¦°øÇÏ´Â ·Îº¿ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á Àü¹®°¡¿Í °£º´ÀÎ ºÎÁ·À¸·Î ÀÎÇØ ȯÀÚ Ä¡·áÀÇ °ø¹éÀ» ¸Þ¿ï ¼ö ÀÖ´Â ·Îº¿ Áö¿ø ½Ã½ºÅÛÀÇ µµÀÔÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ºÐ¾ßÀÇ ·Îº¿ °³¹ß ¹× ÅëÇÕÀ» ÃËÁøÇÏ´Â ½ÃÀå °³Ã´ ÀÌ´Ï¼ÅÆ¼ºêµµ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ½º¸¶Æ®È¨ ¹× Ä¿³ØÆ¼µå ÇコÄÉ¾î »ýŰèÀÇ ºÎ»óÀº IoT ±â±â ¹× ¿ø°ÝÀÇ·á Ç÷§Æû°ú ¿øÈ°ÇÏ°Ô ÅëÇÕµÉ ¼ö ÀÖ´Â ÄÄÆÐ´Ï¾ð ·Îº¿ÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Àΰ£ Á᫐ ·Îº¿ °øÇÐ ¹× °¨¼º AIÀÇ ¿¬±¸ °³¹ßÀÌ È®´ëµÊ¿¡ µû¶ó ÀÌ·¯ÇÑ ·Îº¿ÀÇ ´É·ÂÀÌ °­È­µÇ¾î ÀÇ·á ȯ°æ¿¡¼­ ´õ¿í È¿°úÀûÀ¸·Î ÀÛµ¿ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ±â¼ú ±â¾÷ ¹× ÀÇ·á ¼­ºñ½º Á¦°øÀÚÀÇ AI žÀç ·Îº¿¿¡ ´ëÇÑ ÅõÀÚ È®´ë´Â Çõ½ÅÀ» ÃËÁøÇÏ°í ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °³ÀÎÈ­µÈ ÇコÄÉ¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ÇコÄɾî ÄÄÆÐ´Ï¾ð ·Îº¿ ½ÃÀåÀº Å©°Ô È®´ëµÇ°í ÀÖÀ¸¸ç, ³ëÀÎ Äɾî, Á¤½Å°Ç°­ Áö¿ø, º¸Á¶ ÇコÄÉ¾î ¼­ºñ½ºÀÇ ¹Ì·¡¸¦ À籸¼ºÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(µ¿¹°Çü, ÈÞ¸Ó³ëÀ̵åÇü), ¿¬·ÉÃþ(¾Æµ¿, ¼ºÀÎ, ³ëÀÎ), ÃÖÁ¾»ç¿ë(¿ä¾ç¿ø¡¤³ëÀÎ ÄÉ¾î ¼¾ÅÍ, º´¿ø¡¤Å¬¸®´Ð, ÀçÅà ÇコÄɾî, °³Àοë)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Healthcare Companion Robots Market to Reach US$4.9 Billion by 2030

The global market for Healthcare Companion Robots estimated at US$2.0 Billion in the year 2024, is expected to reach US$4.9 Billion by 2030, growing at a CAGR of 16.0% over the analysis period 2024-2030. Animal-Like Type, one of the segments analyzed in the report, is expected to record a 14.4% CAGR and reach US$3.1 Billion by the end of the analysis period. Growth in the Humanoid Type segment is estimated at 19.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$552.4 Million While China is Forecast to Grow at 20.9% CAGR

The Healthcare Companion Robots market in the U.S. is estimated at US$552.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 20.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.0% and 14.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.7% CAGR.

Global Healthcare Companion Robots Market - Key Trends & Drivers Summarized

Why Are Companion Robots Gaining Popularity in Healthcare?

The rise of healthcare companion robots is transforming patient care by providing emotional support, assisting with daily activities, and enhancing the quality of life for individuals with disabilities or chronic conditions. As the global population ages, there is an increasing need for assistive technologies that help seniors maintain independence while reducing the burden on caregivers. Healthcare companion robots are equipped with artificial intelligence (AI), speech recognition, and machine learning algorithms that enable them to interact with patients, provide reminders for medication adherence, and assist with mobility. These robots are particularly beneficial in elderly care, where they help combat loneliness and cognitive decline by engaging users in interactive conversations and activities. Additionally, individuals with neurodevelopmental disorders such as autism benefit from robotic companions that facilitate social interaction and therapy. The COVID-19 pandemic further highlighted the importance of robotic assistance in minimizing human contact and ensuring continuity of care. Hospitals, nursing homes, and homecare settings are increasingly integrating companion robots into their operations to enhance patient engagement, reduce stress, and improve mental well-being. As robotic technology advances, the role of companion robots in healthcare is expected to expand, offering more personalized and adaptive support to users.

How Are AI, Sensors, and Human-Robot Interaction Shaping This Market?

Advancements in artificial intelligence, sensor technology, and human-robot interaction (HRI) are driving the evolution of healthcare companion robots. AI-powered robots can process natural language, recognize emotions, and learn user preferences over time, making interactions more human-like and personalized. Embedded sensors, including LiDAR, infrared, and touch-sensitive technology, allow robots to navigate spaces autonomously and respond to physical gestures. These technological enhancements have enabled companion robots to assist with daily routines such as fetching objects, providing reminders, and monitoring vital signs. Some advanced robots are even capable of detecting early signs of mental health issues by analyzing speech patterns and behavioral cues. The integration of cloud-based AI further enhances the capabilities of these robots, allowing real-time updates and remote monitoring by healthcare providers. Research in neuro-robotics is also paving the way for robots that can detect cognitive decline and provide therapeutic interventions. The continuous development of HRI is improving the social acceptability of companion robots, making them more intuitive and emotionally responsive. As AI and robotics continue to advance, the potential for healthcare companion robots to become integral members of caregiving teams is steadily increasing.

What Are the Ethical and Regulatory Challenges in Deploying Healthcare Robots?

Despite the promising applications of companion robots in healthcare, several ethical and regulatory challenges must be addressed. Privacy concerns arise as these robots collect and process sensitive patient data, necessitating strict cybersecurity measures and compliance with regulations such as the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR). Additionally, ethical debates persist regarding the emotional reliance on robots and their potential impact on human relationships. Some experts argue that while companion robots provide support, they should not replace human caregivers but rather complement their efforts. The regulatory landscape for healthcare robots is still evolving, with different countries imposing varying safety and certification standards. Ensuring that these robots meet medical device classification criteria and ethical guidelines remains a significant challenge for manufacturers. Furthermore, affordability is a key concern, as the high cost of robotic systems limits accessibility, particularly in low-income regions. To address these issues, governments and regulatory bodies must establish clear guidelines for the safe and ethical deployment of healthcare robots while ensuring affordability and equitable access to this emerging technology.

What Is Driving the Rapid Growth of the Healthcare Companion Robots Market?

The growth in the healthcare companion robots market is driven by several factors, including the increasing aging population, advancements in AI and robotics, and rising demand for assistive healthcare technologies. The growing prevalence of neurodegenerative disorders such as Alzheimer’s and Parkinson’s has led to an increased need for robotic solutions that offer cognitive stimulation and physical assistance. Additionally, the shortage of healthcare professionals and caregivers has accelerated the adoption of robotic support systems to fill gaps in patient care. Government initiatives promoting the development and integration of robotics in healthcare are also fueling market expansion. The rise of smart homes and connected healthcare ecosystems has further boosted the adoption of companion robots, as they seamlessly integrate with IoT devices and telehealth platforms. The expansion of research and development in human-centered robotics and emotional AI is enhancing the capabilities of these robots, making them more effective in healthcare settings. Moreover, growing investments from technology companies and healthcare providers in AI-powered robotics are fostering innovation and driving market growth. As the demand for personalized healthcare solutions continues to rise, the healthcare companion robots market is poised for significant expansion, reshaping the future of elderly care, mental health support, and assistive healthcare services.

SCOPE OF STUDY:

The report analyzes the Healthcare Companion Robots market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Animal-Like Type, Humanoid Type); Age-Group (Children, Adult, Geriatric); End-Use (Nursing Homes & Elderly Care Centers End-Use, Hospitals & Clinics End-Use, Home Healthcare End-Use, Personal Use End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â